CoChat

A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control: 一项评估联合使用磺脲与二甲双胍治疗后血糖仍然控制不佳的2型糖尿病患者加用西格列汀治疗后的安全性与有效性的随机临床试验

Moses, Robert G., Round, Elizabeth, Shentu, Yue, Golm, Gregory T., O'neill, Edward A., Gantz, Ira, Engel, Samuel S., Kaufman, Keith D., Goldstein, Barry J. · 2016 · Journal of Diabetes
Cited by 32

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Background: Type 2 diabetes mellitus (T2DM) treatment generally requires multiple antihyperglycemic agents. When diet, exercise, and treatment with sulfonylurea and metformin do not achieve glycemic goals, several options are available. The present study evaluated the efficacy and tolerability of sitagliptin 100 mg/day added to therapy with sulfonylurea and metformin. Methods: Patients with HbA1c ≥7.5% and ≤10.5% while on a sulfonylurea and metformin were randomized 1: 1 to sitagliptin 100 mg/day or placebo for 24 weeks. At Week 24, patients in the placebo group switched to pioglitazone 30 mg/day and both groups continued treatment for another 30 weeks. Results: Of 427 patients randomized, 339 (79.4%) completed the study. At Week 24, significantly greater (P < 0.001) mean reductions from baseline were seen in the sitagliptin versus placebo group for HbA1c (−0.84% vs −0.16%, respectively), 2‐h post‐meal glucose (−2.0 vs −0.2 mmol/L, respectively) and fasting plasma glucose (−0.7 vs 0.3 mmol/L, respectively). At Week 54, improvements in glycemic control continued. At Week 24, the incidence of adverse events (AEs) was numerically greater with sitagliptin than placebo, primarily because of a higher incidence of hypoglycemia. At Week 54, the incidence of AEs was similar in both groups, primarily because of a higher incidence of hypoglycemia and edema in the placebo/pioglitazone group after Week 24. The only meaningful change in body weight was an increase in the placebo/pioglitazone group at Week 54. Conclusions: In this study, sitagliptin 100 mg/day was generally well tolerated and provided improvement in glycemic control when added to the combination of sulfonylurea and metformin in patients with T2DM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/1753-0407.12351

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 32

Metadata

Authors
Moses, R. G., Round, E., Shentu, Y., Golm, G. T., O'neill, E. A., Gantz, I., Engel, S. S., Kaufman, K. D., & Goldstein, B. J.
Venue
Journal of Diabetes
Publisher
Wiley
Published
2016-02-03
Volume
8
Issue
5
Pages
701-711
ISSN
  • 1753-0393 (ISSN-L)
  • 1753-0407
OpenAlex
W2181940024
Cited by
32
References
6
FWCI
4.05
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control: 一项评估联合使用磺脲与二甲双胍治疗后血糖仍然控制不佳的2型糖尿病患者加用西格列汀治疗后的安全性与有效性的随机临床试验. https://app.cochat.ai/papers/10.1111/1753-0407.12351
The paper
Moses, R. G., Round, E., Shentu, Y., Golm, G. T., O'neill, E. A., Gantz, I., Engel, S. S., Kaufman, K. D., & Goldstein, B. J. (2016). A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control: 一项评估联合使用磺脲与二甲双胍治疗后血糖仍然控制不佳的2型糖尿病患者加用西格列汀治疗后的安全性与有效性的随机临床试验. Journal of Diabetes. https://doi.org/10.1111/1753-0407.12351

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.